A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial.
Alexandra J LanksyRajendra MakkarTamim M NazifSteven R MesseJohn ForrestRahul SharmaJoachim SchoferAxel LinkeDavid BrownAbhijeet DhoblePhillip HorwitzMing ZangFrederico DeMarcoVivek RajagopalMichael G DwyerRobert ZivadinovPieter StellaJoshua RovinHelen PariseSusheel KodaliAndreas BaumbachJeffrey W MosesPublished in: European heart journal (2021)
REFLECT I demonstrated that TG cerebral protection during TAVR was safe in comparison with historical TAVR data but did not meet the predefined effectiveness endpoint compared with unprotected TAVR controls.
Keyphrases
- aortic valve
- transcatheter aortic valve implantation
- aortic stenosis
- transcatheter aortic valve replacement
- aortic valve replacement
- subarachnoid hemorrhage
- ejection fraction
- left ventricular
- randomized controlled trial
- cerebral ischemia
- coronary artery disease
- brain injury
- study protocol
- electronic health record
- systematic review
- clinical trial
- phase ii
- deep learning
- big data
- atrial fibrillation